Clinical trials: Acute Treatment of Migraine, open to volunteers
Acute Migraine
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
- Trial name
- NCT07674654
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TriGemX Bio, Inc.
Acute Headache, Migraine
High- vs Standard-Dose Intravenous Magnesium for Acute Headache
Headache is one of the most common reasons for consultation in emergency departments and represents a significant cause of disability, particularly in patients with migraine and other primary headache disorders.
- Conditions
- Acute Headache, Migraine, Tension-type Headache, Cluster Headache
- Trial name
- MAGHEAD (NCT07779486)
- Testing
- Magnesium Sulfate 2 grams, Magnesium Sulfate 4 G, Paracetamol 1 g
- Where
- Tunisia
- Volunteers
- 300 people
- Sponsor
- University of Monastir
COVID-19, Long COVID
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and…
- Conditions
- COVID-19, Long COVID, Long Covid19, SARS CoV 2 Infection
- Trial name
- NCT05780450
- Testing
- Transcranial Direct Current Therapy (tDCS)
- Where
- 2 sites in Spain
- Volunteers
- 87 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
Vestibular Migraine, Dizziness
Chinese Real-world Study of Treatment of Vestibular Migraine
Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment.
- Conditions
- Vestibular Migraine, Dizziness, Vertigo
- Trial name
- NCT07203248
- Testing
- CGRP R Inhibitor; CGRP Inhibitor, none-CGRP
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Vestibular Migraine
Acute Treatment of Vestibular Migraine by Rimegepant
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
- Trial name
- VM-rime (NCT07871097)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Wensheng Qu
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Migraine
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
- Trial name
- NCT07645924
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- TriGemX Bio, Inc.
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- TriGemX Bio, Inc.
Acute Treatment of Migraine
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack.
- Trial name
- NCT07609914
- Testing
- Rimegepant
- Where
- 24 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Pfizer
Episodic Migraine, Chronic Migraine
i-NEED: NEw migrainE Drugs Database
Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of…
- Conditions
- Episodic Migraine, Chronic Migraine, Medication Overuse Headache
- Trial name
- i-NEED (NCT07103694)
- Testing
- anti-CGRP monoclonal antibodies, gepants, combination of sumatriptan and naproxen
- Where
- 2 sites in Italy
- Volunteers
- 2,641 people
- Sponsor
- IRCCS San Raffaele Roma
Migraine, Migraine With Aura
Gepant treAtments: EffectIveNess and tolERability (GAINER)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- GAINER (NCT05903027)
- Testing
- Rimegepant 75 MG Disintegrating Oral Tablet
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Florence
Migraine
A Phase II Study of NB001 for Acute Migraine Treatment
The goal of this observational study is to Evaluate the Efficacy and Safety of NB001 for the Acute Treatment of Migraine in Adult patients diagnosed with migraine.
- Trial name
- Channel (NCT07577050)
- Testing
- Four tablets of NB001
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Migraine
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of…
- Trial name
- NCT06401642
- Testing
- Zavegepant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Migraine
Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study
This is a multicenter, observational, prospective, real-life study that will be conducted at Headache Centers, aimed at confirming the efficacy and safety of the combination of sumatriptan 85 mg with naproxen 500 mg.
- Trial name
- SMART (NCT06868953)
- Testing
- combination of sumatriptan 85 mg and naproxen 500 mg
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Acute Treatment of Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine.
- Trial name
- NCT06995729
- Testing
- Zavegepant
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie